Bailard, Inc. Novo Nordisk A S Transaction History

Bailard, Inc.

$3.8 Billion
Q3 2024

A detailed history of Bailard, Inc. transactions in Novo Nordisk A S stock. As of the latest transaction made, Bailard, Inc. holds 12,348 shares of NVO stock, worth $1.26 Million. This represents 0.04% of its overall portfolio holdings.

Number of Shares

12,348

Previous 11,503 7.35%

Holding current value

$1.26 Million

Previous $1.64 Million 10.42%

% of portfolio

0.04%

Previous 0.05%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 30, 2024	BUY	$119.07 - $145.42 $100,614 - $122,879	845 Added 7.35%	12,348 $1.47 Million
Q2 2024 Jul 25, 2024	SELL	$122.71 - $146.91 $109,457 - $131,043	-892 Reduced 7.2%	11,503 $1.64 Million
Q1 2024 May 08, 2024	BUY	$102.11 - $135.92 $466,336 - $620,746	4,567 Added 58.34%	12,395 $1.59 Million
Q4 2023 Feb 02, 2024	SELL	$87.78 - $105.45 $31,864 - $38,278	-363 Reduced 4.43%	7,828 $809,000
Q3 2023 Oct 24, 2023	BUY	$90.94 - $199.54 $380,947 - $835,873	4,189 Added 104.67%	8,191 $744,000
Q2 2023 Jul 20, 2023	BUY	$155.98 - $172.65 $65,667 - $72,685	421 Added 11.76%	4,002 $647,000
Q1 2023 May 08, 2023	BUY	$132.34 - $159.14 $3,970 - $4,774	30 Added 0.84%	3,581 $569,000
Q4 2022 Feb 02, 2023	SELL	$102.55 - $135.33 $42,763 - $56,432	-417 Reduced 10.51%	3,551 $480,000
Q3 2022 Oct 18, 2022	BUY	$95.28 - $116.93 $15,340 - $18,825	161 Added 4.23%	3,968 $395,000
Q2 2022 Jul 27, 2022	SELL	$103.24 - $121.81 $42,534 - $50,185	-412 Reduced 9.77%	3,807 $424,000
Q1 2022 Apr 25, 2022	BUY	$93.1 - $112.54 $69,638 - $84,179	748 Added 21.55%	4,219 $469,000
Q4 2021 Feb 10, 2022	BUY	$95.88 - $117.08 $332,799 - $406,384	3,471 New	3,471 $389,000

Others Institutions Holding NVO

# of Institutions

1,948

Shares Held

320M

Call Options Held

5.22M

Put Options Held

6.6M

View Full List

About NOVO NORDISK A S

Ticker NVO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,257,289,984
Market Cap $230B
Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...

More about NVO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Bailard, Inc. with notifications on news.

Account